Loading organizations...
Serial Stage Venture Partners (SSVP) is a venture capital firm focused on early-stage healthcare innovation. It invests in seed and Series A rounds for companies developing AI-enabled medical devices, breakthrough therapeutics, advanced diagnostic platforms, and scalable healthcare software. SSVP targets novel solutions designed to improve patient outcomes and healthcare efficiency through robust technological and business models.
Dr. Raymond R. Rackley, MD, BME, a prominent surgeon and experienced venture investor, founded SSVP as its Managing Partner. He established the firm based on the insight that combining deep clinical expertise with a sophisticated investment network could effectively nurture promising healthcare startups. Dr. Rackley envisioned a collaborative structure for impactful commercial solutions.
SSVP supports early-stage companies and founders in the healthcare technology sector, offering strategic capital and guidance. The firm aims to build a portfolio delivering advancements in medicine and patient care. Its vision is to foster technologies demonstrating commercial viability and contributions to global healthcare.
Serial Stage Venture Partners has 2 tracked investments across 1 company. The latest tracked deal is $25.0M Series B in Alphyn Biologics in December 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 12, 2025 | Alphyn Biologics | $25.0M Series B | Tony Shipley | Angel Physicians Fund |
| Sep 19, 2022 | Alphyn Biologics | $3.3M Series A | Queen City Angels | Angel Physicians Fund |
